Search Within

Evan Gelenn Dio Siau

Formats
  1. Meeting Abstract (4)
  2. Journal Article (3)
Groups
  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (7)
  3. Thoracic Oncology (7)
  4. Department of Pathology and Laboratory Medicine (6)
  5. GSK Faculty (6)
  6. Human Oncology and Pathogenesis Program (6)

More Groups

People
  1. Alexander Drilon (7)
  2. Marc Ladanyi (6)
  3. Romel Somwar (6)
  4. Adam Schoenfeld (4)
  5. Elisa De Stanchina (4)
  6. Gregory Riely (4)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (1)
  4. 2019 (3)
  5. 2017 (1)
Publications
  1. Journal of Thoracic Oncology (2)
  2. Cancer Research (1)
  3. Clinical Cancer Research (1)
  4. Molecular Cancer Research (1)
  5. Neuro-Oncology Advances (1)
  6. Oncoscience (1)
Publishers
  1. American Association for Cancer Research (3)
  2. Elsevier Inc. (2)
  3. Impact Journals (1)
  4. Oxford University Press (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MYC promotes tyrosine kinase inhibitor resistance in ROS1-fusion-positive lung cancer
    Journal Article

    Iyer, S. R.; Odintsov, I.; Schoenfeld, A. J.; Siau, E.; Mattar, M. S.; de Stanchina, E.; Khodos, I.; Drilon, A.; Riely, G. J.; Ladanyi, M.; more...
    Molecular Cancer Research (2022)

    Fulltext@MSK | Save
  • MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion positive lung cancers
    Meeting Abstract

    Iyer, S. R.; Odintsov, I.; Schoenfeld, A. J.; Sato, H.; Siau, E.; Drilon, A.; Riely, G. J.; Somwar, R.; Ladanyi, M.; Davare, M. A.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions
    Journal Article

    Sato, H.; Schoenfeld, A. J.; Siau, E.; Lu, Y. C.; Tai, H.; Suzawa, K.; Kubota, D.; Lui, A. J. W.; Qeriqi, B.; Mattar, M.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Generation and characterization of patient-derived preclinical models from tumor cells isolated from cerebrospinal fluid
    Meeting Abstract

    Offin, M.; Vojnic, M.; Liu, Z.; Lui, A.; Siau, E.; Gladstone, E.; Mattar, M.; Khodos, I.; Drilon, A.; Boire, A.; more...
    Neuro-Oncology Advances (2019)

    Fulltext@MSK | Save
  • A novel activating MAP2K1 in-frame deletion mediates acquired resistance to ROS1 TKIs in a patient with ROS1 fusion-positive NSCLC
    Meeting Abstract

    Sato, H.; Schoenfeld, A.; Siau, E.; Suzawa, K.; Yue, C.; Offin, M.; Drilon, A.; Davare, M.; Riely, G.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Generation and characterization of novel preclinical disease models of NSCLC with NRG1 rearrangements to improve therapy
    Meeting Abstract

    Gladstone, E.; Vojnic, M.; Offin, M.; Delasos, L.; Lui, A.; Siau, E.; Sato, H.; Benayed, R.; Kurth, R.; Mattar, M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Targeting RET-rearranged lung cancers with multikinase inhibitors
    Journal Article

    Sabari, J. K.; Siau, E. D.; Drilon, A.
    Oncoscience (2017)

    Fulltext@MSK | Save